Immune-mediated Colitis from Dual Checkpoint Inhibitors.

Authors

Nishanth Thalambedu, Abington Jefferson HealthFollow
Yasir Khan, Abington Jefferson HealthFollow
Qian Zhang, Abington Jefferson HealthFollow
Shristi Khanal, Abington Jefferson HealthFollow
Ammar Ashfaq, Abington Jefferson HealthFollow

Document Type

Article

Publication Date

11-26-2019

Comments

This article is the author’s final published version in Cureus, Volume 11, Issue 11, November 2019, Article number e6233.

The published version is available at https://doi.org/10.7759/cureus.6233. Copyright © Thalambedu et al.

Abstract

Melanoma is a deadly disease with immunotherapy treatment options that emerged in the last few years and have changed the disease outcome. However, it is associated with immune-related toxic effects despite improving survival. We present the case of a 53-year-old woman who had two weeks of diarrhea after she was treated with dual immunotherapy agents for her advanced melanoma. The final workup revealed pancolitis, possibly due to immunotherapy adverse effects. Initial conservative treatment, unfortunately, did not lead to a clinical improvement until a steroid was introduced. We are reporting this case to alert our fellow physicians about the immune-mediated toxicities of the relatively new checkpoint inhibitors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.

Recommended Citation

Thalambedu, Nishanth; Khan, Yasir; Zhang, Qian; Khanal, Shristi; and Ashfaq, Ammar, "Immune-mediated Colitis from Dual Checkpoint Inhibitors." (2019). Abington Jefferson Health Papers. Paper 44.
https://jdc.jefferson.edu/abingtonfp/44

PubMed ID

31890432

Language

English